Quick Answer
Metagenomi Therapeutics, Inc. reported Total Revenue of $25.21 million for the year ending 2025.
- Metagenomi Therapeutics, Inc. showed a decrease of -51.8% in Total Revenue from 2024 to 2025.
- This data is from Metagenomi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $8.66 million | Q2 2023: $11.34 million | Q3 2023: $12.36 million | Q1 2024: $11.16 million | Q2 2024: $20.01 million | Q3 2024: $11.51 million | Q1 2025: $4.13 million | Q2 2025: $8.51 million | Q3 2025: $8.66 million.
- Over the full 3 years of available data (2023 to 2025), Metagenomi Therapeutics, Inc.'s Total Revenue has declined by 43.7%.
- Historical annual values: Fiscal year 2025: $25.21 million | Fiscal year 2024: $52.30 million | Fiscal year 2023: $44.76 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: